UPDATE | November 18, 2026

Overcoming productivity barriers: Process intensification via N-1 perfusion for high-density fed-batch inoculation

  • MAIL

Overcoming productivity barriers Process intensification via N 1 perfusion for high density fed batch inoculation


Improving upstream productivity requires efficient seed expansion while maintaining the operational simplicity of fed-batch manufacturing. N-1 perfusion offers an approach to achieving higher cell densities for intensified fed-batch inoculation.


This poster presents Samsung Biologics’ S-Tensify™ N-1 perfusion development platform, which uses an alternating tangential flow (ATF) system to achieve high-density seed expansion of up to 100 × 10⁶ cells/mL. The process utilizes readily available commercial media to help mitigate supply chain and sourcing risks while supporting intensified fed-batch manufacturing.


Key highlights include:

  • High-density seed expansion of 60–100 × 10⁶ cells/mL through ATF-based N-1 perfusion
  • Use of readily available commercial media to support supply chain efficiency
  • High-density fed-batch inoculation at 20–30 × 10⁶ cells/mL
  • More than twofold increase in titer compared with conventional fed-batch while maintaining product quality attributes


Discover how S-Tensify™ N-1 perfusion can support upstream process intensification and improve productivity in biologics manufacturing.


Overcoming productivity barriers Process intensification via N 1 perfusion for high density fed batch inoculation


Improving upstream productivity requires efficient seed expansion while maintaining the operational simplicity of fed-batch manufacturing. N-1 perfusion offers an approach to achieving higher cell densities for intensified fed-batch inoculation.


This poster presents Samsung Biologics’ S-Tensify™ N-1 perfusion development platform, which uses an alternating tangential flow (ATF) system to achieve high-density seed expansion of up to 100 × 10⁶ cells/mL. The process utilizes readily available commercial media to help mitigate supply chain and sourcing risks while supporting intensified fed-batch manufacturing.


Key highlights include:
  • - High-density seed expansion of 60–100 × 10⁶ cells/mL through ATF-based N-1 perfusion
  • - Use of readily available commercial media to support supply chain efficiency
  • - High-density fed-batch inoculation at 20–30 × 10⁶ cells/mL
  • - More than twofold increase in titer compared with conventional fed-batch while maintaining product quality attributes


Discover how S-Tensify™ N-1 perfusion can support upstream process intensification and improve productivity in biologics manufacturing.


Share article

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required